An exploratory, randomised, double-blind, placebo controlled, 14 day, two-way crossover, Inhaled Allergen Challenge (IAC) study to evaluate the effects of SMP-028 in subjects with mild to moderate asthma.
Phase of Trial: Phase II
Latest Information Update: 25 Jul 2012
At a glance
- Drugs SMP 028 (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms IAC-SMP028
- Sponsors Dainippon Sumitomo Pharma
- 01 Apr 2010 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
- 17 Nov 2009 New trial record